Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations

被引：15
|
作者：
Bhagwat, Shripad V.
McMillen, William T.
Cai, Shufen
Zhao, Baohui
Whitesell, Matthew
Kindler, Lisa
Flack, Robert S.
Wu, Wenjuan
Huss, Karen
Anderson, Bryan
Yuan, Xiu-Juan
Jaken, Susan
McCann, Denis
Mathes, Brian
Dropsey, Andrew J.
Manro, Jason
Walgren, Jennie
Yuen, Eunice
Gong, Xueqian
Rodriguez, Michael J.
Huang, Jianping
Tiu, Ramon V.
Joseph, Sajan
Peng, Sheng-Bin
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4973
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4973
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Identifying high quality, potent and selective pyrimidinylthienopyrrolone inhibitors of ERK1/2 kinase: LY3214996
    Zhao, Gaiying
    McMillen, William T.
    Cai, Shufen
    Zhao, Baohui
    Whitesell, Matthew
    Wu, Wenjuan
    Huss, Karen
    Anderson, Bryan
    Yuan, Xiu-Juan
    Jaken, Susan
    Kindler, Lisa
    Flack, Robert S.
    McCann, Denis
    Mathes, Brian
    Dropsey, Andrew J.
    Walgren, Jennie
    Yuen, Eunice
    Manro, Jason
    Gong, Xueqian
    Cortez, Guillermo
    McLean, Johnathan
    Rodriguez, Michael J.
    Tiu, Ramon V.
    Bhagwat, Shripad V.
    Joseph, Sajan
    [J]. CANCER RESEARCH, 2017, 77
  • [2] Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4 and CDK6 inhibitor (abemaciclib) enhances antitumor efficacy in KRAS mutant non-small cell lung cancer (NSCLC)
    Wu, Wenjuan
    Bhagwat, Shripad V.
    King, Constance
    Pratt, Susan
    Gong, Xueqian
    Stewart, Julie
    Jones, Bonita
    Flack, Robert
    Beckman, Richard
    Falcon, Beverly
    Manro, Jason
    McMillen, William T.
    Tiu, Ramon V.
    Peng, Sheng-Bin
    Reinhard, Christoph
    Joseph, Sajan
    Buchanan, Sean
    [J]. CANCER RESEARCH, 2017, 77
  • [3] Combination of an ERK1/2 inhibitor (LY3214996) with VEGFR-2 inhibitor enhances anti-tumor activity in KRAS mutant non-small cell lung cancer
    Wu, Wenjuan
    Bhagwat, Shripad V.
    Jones, Bonita D.
    Swearingen, Michelle L.
    Falcon, Beverly L.
    McMillen, William T.
    Joseph, Sajan
    Buchanan, Sean
    Peng, Sheng-Bin
    Reinhard, Christoph
    Tiu, Ramon V.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [4] A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.
    Taza, Fadi
    Durm, Greg Andrew
    Opyrchal, Mateusz
    Jalal, Shadia Ibrahim
    Radovich, Milan
    Schneider, Bryan P.
    Turk, Anita Ahmed
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitor
    Flemington, Vikki
    Simpson, Iain
    Davies, Emma
    Robinson, David
    Lindsay, Nicola
    Hanson, Lyndsey
    Hopcroft, Philip
    Tonge, Michael
    Roberts, Karen
    Ward, Richard
    [J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [6] Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity in KRAS mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)
    Wu, Wenjuan
    Bhagwat, Shripad
    Kindler, Lisa
    McMillen, William
    Joseph, Sajan
    Buchanan, Sean
    Reinhard, Christoph
    Tiu, Ramon V.
    Peng, Sheng-Bin
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [7] Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
    Germann, Ursula A.
    Furey, Brinley F.
    Markland, William
    Hoover, Russell R.
    Aronov, Alex M.
    Roix, Jeffrey J.
    Hale, Michael
    Boucher, Diane M.
    Sorrell, David A.
    Martinez-Botella, Gabriel
    Fitzgibbon, Matthew
    Shapiro, Paul
    Wick, Michael J.
    Samadani, Ramin
    Meshaw, Kathryn
    Groover, Anna
    DeCrescenzo, Gary
    Namchuk, Mark
    Emery, Caroline M.
    Saha, Saurabh
    Welsch, Dean J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2017, 16 (11) : 2351 - 2363
  • [8] Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development
    Robarge, Kirk
    Schwarz, Jacob
    Blake, Jim
    Burkard, Michael
    Chan, Jocelyn
    Chen, Huifen
    Chou, Kang-Jye
    Diaz, Dolores
    Gaudino, John
    Gould, Stephen
    Grina, Jonas
    Xin Linghu
    Liu, Lichuan
    Martinson, Matthew
    Moreno, David A.
    Orr, Christine
    Pacheco, Patricia
    Qin, Ann
    Rasor, Kevin
    Ren, Li
    Shahidi-Latham, Sheerin
    Stults, Jeffrey
    Sullivan, Francis
    Wang, Weiru
    Yin, Peter
    Zhou, Aihe
    Belvin, Marcia
    Merchant, Mark
    Moffat, John G.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [9] Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development
    Schwarz, Jacob
    Blake, James
    Burkard, Michael
    Chan, Jocelyn
    Chen, Huifen
    Chou, Kang-Jye
    Diaz, Dolores
    Dudley, Danette
    Gaudino, John
    Gould, Stephen
    Grina, Jonas
    Hunsaker, Thomas
    Liu, Lichuan
    Martinson, Matthew
    Moreno, David
    Orr, Christine
    Pacheco, Patricia
    Qin, Ann
    Rasor, Kevin
    Ren, Li
    Robarge, Kirk
    Shahidi-Latham, Sheerin
    Stults, Jeffrey
    Sullivan, Francis
    Wang, Weiru
    Yin, Jianping
    Zhou, Aihe
    Belvin, Marcia
    Merchant, Mark
    Moffat, John
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [10] HH2710, a highly potent and selective erk1/2 inhibitor for the treatment of mapk mutant tumors
    Li, Lei
    Huang, Min
    Li, Leping
    Chen, Yi
    Tang, Shuai
    Su, Yi
    Dong, Ruiping
    Ding, Jian
    Geng, Meiyu
    [J]. CANCER RESEARCH, 2020, 80 (16)
12345